US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Impact Biomedical, Inc.

0.4580

-0.0120-2.55%

Post-market: 0.4489-0.0091-1.99%18:25 EST

Volume:54.67K

Turnover:24.78K

Market Cap:48.09M

PE:-0.12

High:0.4700

Open:0.4474

Low:0.4358

Close:0.4700

52wk High:6.17

52wk Low:0.3621

Shares:105.00M

Float Shares:11.64M

Volume Ratio:0.57

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.6869

EPS(LYR):-2.2969

ROE:-346.99%

ROA:-7.68%

PB:-4.05

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Universal Ibogaine Seeks Cease Trade Order Amid Financial Filing Delays

Impact Biomedical Inc. held annual shareholder meeting

Impact BioMedical Converts Preferred Stock to Common

Universal Ibogaine Restructures Board Ahead of Clinical Trial Submission

Impact Biomedical Inc. Announces Date for 2025 Annual Stockholders Meeting

Universal Ibogaine Announces Key Outcomes from Annual Shareholder Meeting

Impact BioMedical Inc. Approves Issuance of 31.9 Million Shares to DSS, Inc

Impact BioMedical Inc. Approves Issuance of 31.9 Million Shares to DSS, Inc

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

Impact BioMedical Q2 EPS $(1.18), Sales $7.00K

Impact BioMedical Inc. Approves 2023 Equity Incentive Plan and Reserves 5 Million Common Stock Shares

DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares

Impact Biomedical Inc - to Issue 31,939,778 Shares to Settle Debt - SEC Filing

THOMSON REUTERS

Impact Biomedical Inc - on July 21, Enters Debt Conversion Agreement With Dss - SEC Filing

THOMSON REUTERS

Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock

Impact BioMedical Inc. Approves 2023 Equity Incentive Plan, Reserving 5 Million Shares for Issuance

Top Midday Gainers

MT Newswires Live

Crude Oil Falls 1%; US Services PMI Declines In June

Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger to Enhance Global Pharmaceutical Innovation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBO\",,,,,undefined,":{"symbol":"IBO","market":"US","secType":"STK","nameCN":"Impact Biomedical, Inc.","latestPrice":0.458,"timestamp":1764968400000,"preClose":0.47,"halted":0,"volume":54668,"hourTrading":{"tag":"盘后","latestPrice":0.4489,"preClose":0.458,"latestTime":"18:25 EST","volume":1722,"amount":775.4885,"timestamp":1764977149876},"delay":0,"floatShares":11638100,"shares":105000000,"eps":-3.686859,"marketStatus":"Closed","change":-0.012,"latestTime":"12-05 16:00:00 EST","open":0.4474,"high":0.47,"low":0.4358,"amount":24777.833656,"amplitude":0.072766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.686859,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1721361600000,"exchange":"AMEX","adjPreClose":0.47,"preHourTrading":{"tag":"盘前","latestPrice":0.4395,"preClose":0.47,"latestTime":"09:09 EST","volume":2779,"amount":1228.01356055,"timestamp":1764943759087},"postHourTrading":{"tag":"盘后","latestPrice":0.4489,"preClose":0.458,"latestTime":"18:25 EST","volume":1722,"amount":775.4885,"timestamp":1764977149876},"volumeRatio":0.571327,"impliedVol":0.2695,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBO\",,,,,undefined,":{"symbol":"IBO","floatShares":11638100,"roa":"-7.68%","roe":"-346.99%","lyrEps":-2.296891,"volumeRatio":0.571327,"shares":105000000,"dividePrice":0,"high":0.47,"amplitude":0.072766,"preClose":0.47,"low":0.4358,"week52Low":0.3621,"pbRate":"-4.05","psRate":"1923.60","week52High":6.17,"institutionHeld":0,"latestPrice":0.458,"eps":-3.686859,"divideRate":0,"volume":54668,"delay":0,"ttmEps":-3.686859,"open":0.4474,"prevYearClose":1.45,"prevWeekClose":0.446,"prevMonthClose":0.446,"prevQuarterClose":0.6648,"fiveDayClose":0.446,"twentyDayClose":0.5338,"sixtyDayClose":0.6553},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IBO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IBO","date":"2025-12-04","current":-0.124225,"percent":0.184211,"low":-7.852882,"twenty":-0.518249,"median":-0.209261,"eighty":15.819172,"high":48.978211,"avg":4.712028,"sd":10.158729,"marketCap":45740402},"quantilePoints":[{"date":"2024-09-20","current":-6.823884,"twenty":-6.997189,"median":-6.647871,"eighty":-6.406869,"marketCap":28974211},{"date":"2024-09-27","current":-6.471858,"twenty":-6.910536,"median":-6.471858,"eighty":-6.309385,"marketCap":27479510},{"date":"2024-10-04","current":-4.468019,"twenty":-6.775142,"median":-6.309385,"eighty":-5.239768,"marketCap":18971209},{"date":"2024-10-11","current":-4.260324,"twenty":-6.580174,"median":-5.415781,"eighty":-4.180929,"marketCap":18089336},{"date":"2024-10-18","current":-3.864701,"twenty":-6.471858,"median":-5.077294,"eighty":-4.002262,"marketCap":16409521},{"date":"2024-10-25","current":-4.738808,"twenty":-6.374374,"median":-4.468019,"eighty":-3.910194,"marketCap":20120980},{"date":"2024-10-31","current":-5.984438,"twenty":-6.309385,"median":-5.036676,"eighty":-3.937273,"marketCap":25409923},{"date":"2024-11-08","current":-7.552848,"twenty":-6.791389,"median":-5.368393,"eighty":-3.986015,"marketCap":32069393},{"date":"2024-11-15","current":24.785345,"twenty":-7.039432,"median":-5.415781,"eighty":-3.937273,"marketCap":28874927},{"date":"2024-11-22","current":25.871555,"twenty":-6.952238,"median":-5.077294,"eighty":-3.531089,"marketCap":30140362},{"date":"2024-11-29","current":28.833947,"twenty":-6.807637,"median":-4.603414,"eighty":19.151303,"marketCap":33591548},{"date":"2024-12-06","current":22.514178,"twenty":-6.688489,"median":-4.260324,"eighty":24.785345,"marketCap":26229017},{"date":"2024-12-13","current":21.230475,"twenty":-6.471858,"median":-4.053712,"eighty":24.548354,"marketCap":24733503},{"date":"2024-12-20","current":16.490647,"twenty":-6.439363,"median":-3.95352,"eighty":23.560889,"marketCap":19211604},{"date":"2024-12-27","current":15.799423,"twenty":-6.309385,"median":-3.885823,"eighty":23.402895,"marketCap":18406328},{"date":"2025-01-03","current":15.206944,"twenty":-6.309385,"median":-3.628573,"eighty":23.007909,"marketCap":17716090},{"date":"2025-01-10","current":17.774351,"twenty":-6.27689,"median":-3.439292,"eighty":22.790667,"marketCap":20707119},{"date":"2025-01-17","current":15.898169,"twenty":-6.092754,"median":12.787657,"eighty":22.593175,"marketCap":18521367},{"date":"2025-01-24","current":15.503184,"twenty":-5.93028,"median":14.167144,"eighty":22.435181,"marketCap":18061209},{"date":"2025-01-31","current":18.308568,"twenty":-5.773222,"median":14.515719,"eighty":22.000696,"marketCap":21329482},{"date":"2025-02-07","current":18.663068,"twenty":-5.562007,"median":14.960078,"eighty":21.408218,"marketCap":21742474},{"date":"2025-02-14","current":21.230475,"twenty":-5.415781,"median":15.40345,"eighty":21.8822,"marketCap":24733503},{"date":"2025-02-21","current":19.749279,"twenty":-5.396826,"median":15.503184,"eighty":21.526713,"marketCap":23007910},{"date":"2025-02-28","current":15.206944,"twenty":-5.280387,"median":15.799423,"eighty":21.467465,"marketCap":17716090},{"date":"2025-03-07","current":11.948313,"twenty":-5.101666,"median":15.503184,"eighty":21.230475,"marketCap":13919785},{"date":"2025-03-14","current":6.617983,"twenty":-4.977102,"median":15.305197,"eighty":21.210726,"marketCap":7709950},{"date":"2025-03-21","current":20.53925,"twenty":-4.68465,"median":15.206944,"eighty":21.092229,"marketCap":23928226},{"date":"2025-03-28","current":22.514178,"twenty":-4.44094,"median":15.403944,"eighty":21.526713,"marketCap":26229017},{"date":"2025-04-04","current":-0.226956,"twenty":-4.318165,"median":15.206944,"eighty":21.467465,"marketCap":5607631},{"date":"2025-04-11","current":-0.249456,"twenty":-4.247705,"median":14.713213,"eighty":21.230475,"marketCap":6163560},{"date":"2025-04-17","current":-0.21375,"twenty":-4.19723,"median":14.416973,"eighty":21.230475,"marketCap":5281325},{"date":"2025-04-25","current":-0.20788,"twenty":-4.061836,"median":14.219481,"eighty":21.131728,"marketCap":5136300},{"date":"2025-05-02","current":-0.195652,"twenty":-4.045588,"median":14.120734,"eighty":20.934235,"marketCap":4834164},{"date":"2025-05-09","current":-0.243342,"twenty":-4.034757,"median":11.653062,"eighty":20.934235,"marketCap":6012492},{"date":"2025-05-16","current":-0.248299,"twenty":-3.95352,"median":8.822497,"eighty":20.931273,"marketCap":6210693},{"date":"2025-05-23","current":-0.265741,"twenty":-3.926441,"median":6.617983,"eighty":20.53925,"marketCap":6646976},{"date":"2025-05-30","current":-0.236751,"twenty":-3.893947,"median":6.024517,"eighty":20.53925,"marketCap":5921851},{"date":"2025-06-06","current":-0.240616,"twenty":-3.868925,"median":5.431051,"eighty":20.065268,"marketCap":6018535},{"date":"2025-06-13","current":-0.228296,"twenty":-3.675799,"median":-0.196924,"eighty":19.788778,"marketCap":5710357},{"date":"2025-06-20","current":-0.208921,"twenty":-3.531089,"median":-0.205288,"eighty":19.749279,"marketCap":5225732},{"date":"2025-06-27","current":-0.444512,"twenty":-3.450015,"median":-0.207718,"eighty":19.630783,"marketCap":11118579},{"date":"2025-07-03","current":-0.315507,"twenty":-3.41752,"median":-0.208564,"eighty":19.492537,"marketCap":7891774},{"date":"2025-07-11","current":-0.276757,"twenty":-2.342076,"median":-0.2115,"eighty":19.265421,"marketCap":6922523},{"date":"2025-07-18","current":-0.337104,"twenty":-0.74982,"median":-0.215206,"eighty":19.038305,"marketCap":8431991},{"date":"2025-07-25","current":-0.333674,"twenty":-0.612978,"median":-0.222159,"eighty":18.909935,"marketCap":8346185},{"date":"2025-08-01","current":-0.294972,"twenty":-0.468414,"median":-0.227287,"eighty":18.761815,"marketCap":7378144},{"date":"2025-08-08","current":-0.284053,"twenty":-0.45663,"median":-0.231823,"eighty":18.722316,"marketCap":7105013},{"date":"2025-08-15","current":-0.273955,"twenty":-0.436592,"median":-0.234874,"eighty":18.663068,"marketCap":6852428},{"date":"2025-08-22","current":-0.188262,"twenty":-0.41717,"median":-0.231823,"eighty":18.521268,"marketCap":7243008},{"date":"2025-08-29","current":-0.18606,"twenty":-0.405543,"median":-0.227287,"eighty":18.292374,"marketCap":7158283},{"date":"2025-09-05","current":-0.184588,"twenty":-0.400413,"median":-0.223319,"eighty":18.268082,"marketCap":7101658},{"date":"2025-09-12","current":-0.207551,"twenty":-0.378605,"median":-0.215733,"eighty":18.169336,"marketCap":7985100},{"date":"2025-09-19","current":-0.208501,"twenty":-0.365363,"median":-0.215554,"eighty":17.754602,"marketCap":8021656},{"date":"2025-09-26","current":-0.205207,"twenty":-0.359697,"median":-0.214679,"eighty":17.655855,"marketCap":7894928},{"date":"2025-10-03","current":-0.204162,"twenty":-0.344709,"median":-0.211774,"eighty":17.555134,"marketCap":7854716},{"date":"2025-10-10","current":-0.197922,"twenty":-0.342409,"median":-0.21056,"eighty":17.430516,"marketCap":7614663},{"date":"2025-10-17","current":-0.190511,"twenty":-0.339607,"median":-0.20889,"eighty":17.24033,"marketCap":7329525},{"date":"2025-10-24","current":-0.184968,"twenty":-0.338302,"median":-0.208343,"eighty":17.023878,"marketCap":7116280},{"date":"2025-10-31","current":-0.166598,"twenty":-0.336418,"median":-0.208076,"eighty":16.727639,"marketCap":6409526},{"date":"2025-11-07","current":-0.169068,"twenty":-0.333268,"median":-0.207551,"eighty":16.464578,"marketCap":6504572},{"date":"2025-11-14","current":-1.207414,"twenty":-0.342409,"median":-0.208076,"eighty":16.307374,"marketCap":53356827},{"date":"2025-11-21","current":-1.065365,"twenty":-0.378605,"median":-0.208343,"eighty":16.056163,"marketCap":47079553},{"date":"2025-11-28","current":-1.055895,"twenty":-0.424711,"median":-0.208858,"eighty":15.898169,"marketCap":46661069},{"date":"2025-12-04","current":-1.035061,"twenty":-0.518249,"median":-0.209261,"eighty":15.819172,"marketCap":45740402}],"updateTime":1764989180713},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586340411","title":"Universal Ibogaine Seeks Cease Trade Order Amid Financial Filing Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2586340411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586340411?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:05","pubTimestamp":1764108331,"startTime":"0","endTime":"0","summary":"Universal Ibogaine Inc ( ($TSE:IBO) ) has issued an announcement. Universal Ibogaine Inc. has applied for a management cease trade order (MCTO) due...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-seeks-cease-trade-order-amid-financial-filing-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-seeks-cease-trade-order-amid-financial-filing-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IBO","UVV","BK4075"],"gpt_icon":0},{"id":"2581048866","title":"Impact Biomedical Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581048866","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581048866?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:15","pubTimestamp":1762463715,"startTime":"0","endTime":"0","summary":"Impact Biomedical Inc. held its annual meeting of stockholders on November 5, 2025. During the meeting, stockholders approved the election of Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose to the board of directors. The appointment of Grassi & Co. Certified Public Accountants, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3l9MFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEI","BK4563","BK4007","BK4024","IBO"],"gpt_icon":0},{"id":"2578072675","title":"Impact BioMedical Converts Preferred Stock to Common","url":"https://stock-news.laohu8.com/highlight/detail?id=2578072675","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578072675?lang=en_us&edition=fundamental","pubTime":"2025-10-28 04:35","pubTimestamp":1761597320,"startTime":"0","endTime":"0","summary":"Impact BioMedical, Inc. ( ($IBO) ) has shared an update. On October 30, 2023, Impact BioMedical, Inc. announced that DSS BioHealth Security, Inc. h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/impact-biomedical-converts-preferred-stock-to-common?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/impact-biomedical-converts-preferred-stock-to-common?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBO","BK4007"],"gpt_icon":0},{"id":"2569741867","title":"Universal Ibogaine Restructures Board Ahead of Clinical Trial Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2569741867","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569741867?lang=en_us&edition=fundamental","pubTime":"2025-09-24 05:42","pubTimestamp":1758663760,"startTime":"0","endTime":"0","summary":"Universal Ibogaine Inc ( ($TSE:IBO) ) has issued an announcement. Universal Ibogaine Inc. announced changes to its Board of Directors, with several...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-restructures-board-ahead-of-clinical-trial-submission?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-restructures-board-ahead-of-clinical-trial-submission?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBO","UVV","BK4007","BK4075"],"gpt_icon":0},{"id":"2569712650","title":"Impact Biomedical Inc. Announces Date for 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712650?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:39","pubTimestamp":1758645556,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc. is set to hold its Annual Meeting of Stockholders on November 5, 2025, at their Houston location. The meeting will cover key resolutions, including the election of eight director nominees to serve until the next annual meeting, the ratification of Grassi & Co. Certified Public Accountants, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2025, and an advisory vote to approve executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL5jrcsS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AEI","IBO","BK4563","BK4024"],"gpt_icon":0},{"id":"2567519868","title":"Universal Ibogaine Announces Key Outcomes from Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2567519868","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567519868?lang=en_us&edition=fundamental","pubTime":"2025-09-15 13:08","pubTimestamp":1757912901,"startTime":"0","endTime":"0","summary":"An update from Universal Ibogaine Inc ( ($TSE:IBO) ) is now available. Universal Ibogaine Inc. held its annual meeting of shareholders, where nine ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-announces-key-outcomes-from-annual-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/universal-ibogaine-announces-key-outcomes-from-annual-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4075","IBO","BK4007","UVV"],"gpt_icon":0},{"id":"2566186645","title":"Impact BioMedical Inc. Approves Issuance of 31.9 Million Shares to DSS, Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2566186645","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566186645?lang=en_us&edition=fundamental","pubTime":"2025-09-10 05:04","pubTimestamp":1757451852,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc., a Nevada-based corporation, has announced that its Board of Directors and shareholders holding a majority of the company's outstanding voting capital stock have approved certain actions. The details of these decisions, which were taken on July 14, 2025, will become effective on a future date. Impact BioMedical Inc. is headquartered in Houston, Texas. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 09, 2025, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL5kMgM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEI","BK4007","BK4024","DSS","IBO","BK4563","BK4087"],"gpt_icon":0},{"id":"2562773111","title":"Impact BioMedical Inc. Approves Issuance of 31.9 Million Shares to DSS, Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2562773111","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562773111?lang=en_us&edition=fundamental","pubTime":"2025-08-26 21:15","pubTimestamp":1756214146,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc., a Nevada-based corporation, announced that its Board of Directors and majority stockholders have approved certain key actions. These decisions were finalized on July 14, 2025, and will be implemented following a designated period. The company, headquartered in Houston, Texas, continues to focus on advancing its strategic objectives and fostering growth in the biomedical sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 25, 2025, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL6D11np:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4563","IBO","AEI","BK4087","DSS","BK4024"],"gpt_icon":0},{"id":"2560188843","title":"Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2560188843","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560188843?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520200,"startTime":"0","endTime":"0","summary":"HOUSTON, Aug.  18, 2025  (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/18/3135021/0/en/Impact-Biomedical-Inc-IBO-Announces-3F-US-Patent-Issue.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBIO","BK4007","BK4568","IBO","BK4139"],"gpt_icon":0},{"id":"2559676509","title":"Impact BioMedical Q2 EPS $(1.18), Sales $7.00K","url":"https://stock-news.laohu8.com/highlight/detail?id=2559676509","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559676509?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:48","pubTimestamp":1755208108,"startTime":"0","endTime":"0","summary":"Impact BioMedical (AMEX:IBO) reported quarterly losses of $(1.18) per share.  The company reported $7.00 thousand in sales this quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47142971/impact-biomedical-q2-eps-1-18-sales-7-00k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Impact BioMedical Q2 EPS $(1.18), Sales $7.00K","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBO"],"gpt_icon":0},{"id":"2557314673","title":"Impact BioMedical Inc. Approves 2023 Equity Incentive Plan and Reserves 5 Million Common Stock Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2557314673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557314673?lang=en_us&edition=fundamental","pubTime":"2025-08-06 04:34","pubTimestamp":1754426049,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc., a Nevada corporation based in Houston, Texas, announced that its board of directors and shareholders holding a majority of the company's outstanding voting capital stock have approved certain corporate actions. These resolutions were formalized on August 5, 2025, and are expected to be implemented in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL6ySXZm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEI","BK4563","IBO","BK4024","BK4007"],"gpt_icon":0},{"id":"2555202446","title":"DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2555202446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555202446?lang=en_us&edition=fundamental","pubTime":"2025-07-31 04:14","pubTimestamp":1753906453,"startTime":"0","endTime":"0","summary":"On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3bBlZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","IBO","BK4563","BK4007","DSS","BK4024","AEI"],"gpt_icon":0},{"id":"2554794770","title":"Impact Biomedical Inc - to Issue 31,939,778 Shares to Settle Debt - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2554794770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554794770?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:12","pubTimestamp":1753715576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP1FU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IBO"],"gpt_icon":0},{"id":"2554277079","title":"Impact Biomedical Inc - on July 21, Enters Debt Conversion Agreement With Dss - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2554277079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554277079?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:12","pubTimestamp":1753715576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nFWN3TP1FU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBO","BK4007"],"gpt_icon":0},{"id":"2554702687","title":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2554702687","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554702687?lang=en_us&edition=fundamental","pubTime":"2025-07-28 23:06","pubTimestamp":1753715168,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock. Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLlyJpC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","IBO","BK4024","DSS","BK4007","BK4563","AEI"],"gpt_icon":0},{"id":"2552178269","title":"Impact BioMedical Inc. Approves 2023 Equity Incentive Plan, Reserving 5 Million Shares for Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2552178269","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552178269?lang=en_us&edition=fundamental","pubTime":"2025-07-17 04:31","pubTimestamp":1752697869,"startTime":"0","endTime":"0","summary":"Impact BioMedical Inc., a Nevada-based corporation, has announced that its Board of Directors, along with shareholders holding a majority of the company's outstanding voting capital stock, have approved certain actions. These decisions were made on June 9, 2025, and are set to become effective after a specified period. The company's principal executive offices are located in Houston, Texas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL5k37y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AEI","BK4024","IBO","BK4563"],"gpt_icon":0},{"id":"2545412294","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2545412294","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545412294?lang=en_us&edition=fundamental","pubTime":"2025-06-24 02:12","pubTimestamp":1750702332,"startTime":"0","endTime":"0","summary":"Impact BioMedical  said Monday it agreed to merge with Hong Kong-based pharmaceutical group Dr. Ashleys that will result in a newly formed entity under \"Dr Ashleys Limited.\"Shares of Impact jumped 350%, with intraday trading volume of over 379 million against a daily average of about 6.81 million.Cidara Therapeutics  shares doubled after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults met its primary and all secondary efficacy endpoints for all dose groups.RBC raised its price target on the stock to $75 from $35 while maintaining its outperform rating.More than 5.25 million shares of Cidara traded intraday, compared with a daily average of about 171,000.SpartanNash  said it agreed to be acquired by C&S Wholesale Grocers for $26.90 per share for a total purchase price of $1.77 billion.Shares of SpartanNash soared 50% as trading volume surged to over 7.1 million shares from a daily average of roughly 323,000.Price: 1.70","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDTX","IBO","SPTN","BK4139","BK4102","BK4007"],"gpt_icon":0},{"id":"2545462964","title":"Crude Oil Falls 1%; US Services PMI Declines In June","url":"https://stock-news.laohu8.com/highlight/detail?id=2545462964","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545462964?lang=en_us&edition=fundamental","pubTime":"2025-06-24 00:33","pubTimestamp":1750696426,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/06/46057372/crude-oil-falls-1-us-services-pmi-declines-in-june","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","BK4196","BK4139","NVIW.SI","CDTX","SPTN","BK4102",".IXIC","TSYW.SI","QID","NQmain","CMPS","USAW.SI","IBO","BK4007","QLD","SQQQ","USJW.SI","TQQQ","MNQmain"],"gpt_icon":1},{"id":"2545304419","title":"Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger to Enhance Global Pharmaceutical Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545304419","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545304419?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:46","pubTimestamp":1750679185,"startTime":"0","endTime":"0","summary":"Impact Biomedical Inc. has announced a significant merger with Dr. Ashleys Limited, resulting in a newly formed entity that will trade on the NYSE American under the name \"Dr Ashleys Limited.\" This strategic move will see Dr. Ashleys acquire Impact Biomedical through a reverse merger, integrating Impact Biomedical's intellectual property portfolio into Dr. Ashleys' research and development efforts. The merger aims to accelerate the development of innovative pharmaceutical treatments and expand their global reach. Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, emphasized the milestone's importance in bringing groundbreaking therapies to patients worldwide. Frank D. Heuszel, CEO of Impact Biomedical Inc., expressed excitement about the collaboration, highlighting Dr. Ashleys' global reach and resources that will help bring their innovations to market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLzmT0z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4563","BK4024","IBO","AEI"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}